All News
SOCS1 Insufficiency - a Rare Inborn Error of Immunity
Lancet Rheumatology has published a population study of the rare suppressor of cytokine signalling 1 (SOCS1) insufficiency - an inborn error of immunity affecting the negative regulation of cytokine and growth factor signalling.
Read Article
Ankle Fusion or Total Replacement?
In a large study of British patients needing surgical treatment for advanced arthritis in the ankle, fusion appeared to be a better option than total ankle replacement.
Read Article
Diagnoses via Immune ‘Fingerprints’
Science and researchers at Stanford Medicine have reported the use of Mal-ID (machine learning for immunological diagnosis) to analyze B and T cell receptors sequences from human blood, showing the ability to predict health status (healthy vs diseased) and discriminate between distinct autoimmune diseases or viral infections, and those who had received an influenza vaccine.
Read Article
B Cell Depleters (2.21.2025)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Selective mutation of Traf1/cIAP2 (V196) interaction attenuates inflammatory responses that may contribute to rheumatoid arthritis activity. THis may lead to a new class of therapies for RA https://t.co/kYqAqGsSEA https://t.co/JWUN6iTvxa
Dr. John Cush RheumNow ( View Tweet)
I ALWAYS recommend paraffin wax baths for stiffness, RA, OA, PSS, etc.
Here are some instructions for home use https://t.co/CTI4K2kHf9 https://t.co/i0kO99vdYc
Dr. John Cush RheumNow ( View Tweet)
Retrospect. study of 77 RA pts w/ +ANCA (age 62 yrs, 79%F. 65% RF+. 45% p-ANCA+; 42% MPO+. Diagnoses included: AAV (29%); GPA (45%), MPA (36 %); EGPA (5%). Renal (41%) & upper Resp (36%) were most freq. Pts w/ RA+AAV had more RF, MPO+, nodules, inflam eye Dz… https://t.co/NTvAhZY2y8 https://t.co/IAkWHtcTCo
Dr. John Cush RheumNow ( View Tweet)
Optimal Management of Rheumatoid Arthritis Patients and Liver Disease
https://t.co/4JfUueF55o https://t.co/hBkgYU1Mye
Dr. John Cush RheumNow ( View Tweet)
B Cell Depleters (2.21.2025)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.
https://t.co/PRjy4a1BG9 https://t.co/3J4NSmn6Su
Dr. John Cush RheumNow ( View Tweet)
ACPA+ linked to nodule progression. 208 #RA pts w/ Chest CT studied. Lung nodules seen in 1/3; 10% before RA Dx (10.4 mos before). Positive ACPA (not RF) was assoc w/ nodule progression (OR 3.69). csDMARDs & b/ts-DMARDs NO affect on nodule progression. https://t.co/GO1wLRIl9j https://t.co/pfFGbPv2DG
Dr. John Cush RheumNow ( View Tweet)
US nationwide claims data study of CV outcomes (MACE) in #RA based on b/tsDMARD (n=34375) exposures (71% TNFi, 10% JAKi, 8% ABA, 5% RTX, 5% IL-6i). Compared to TNFi, RTX (HR 1.5) & IL-6i (HR 1.3) had numerically higher, but not statistically significant, MACE risk.… https://t.co/GXunfMY3US https://t.co/XYZPt0kzGE
Dr. John Cush RheumNow ( View Tweet)
Srudy of 558 #RA pts finds GERD symptoms were significantly w/ higher TJC28 and VAS scores and lower use of MTX (but not related to NSAID or steroid use). GERD Sxs may impact MTX dosing and Dz activity measures in RA https://t.co/2H8RUNywlG https://t.co/ZBSlTL1ZA3
Dr. John Cush RheumNow ( View Tweet)
Optimal Management of Rheumatoid Arthritis Patients and Liver Disease
https://t.co/29CG4bwlYR
Dr. John Cush RheumNow ( View Tweet)
CRP and Hidradenitis Supprativa
A post hoc analysis of 2 phase 3 randomized clinical trials (PIONEER I and II) of adalimumab vs Placebo in patients with active Hidradenitis suppurativa (HS) demonstrated more severe HS that was associated with elevated CRP had a higher BMI.… https://t.co/VxFRjt3cRw https://t.co/rdNIvzMaP8
Dr. John Cush RheumNow ( View Tweet)
Full read, comprehensive review of Hidradenitis Supprativa in Lancet Feb 1, 2025
Common assn; DM, IBD, Smoking, Obesity, metabolic syndr, NASH, SpA, RA
FDA approved Rx: Adalimumab, Secukinumab, Bimekizumab https://t.co/9er7TkNXpK https://t.co/N6sal9URv3
Links:
Dr. John Cush RheumNow ( View Tweet)
Risk for Serious Infection with Low-Dose Glucocorticoids in RA
https://t.co/5frAX3W7Hz https://t.co/PHeqCacxKa
Dr. John Cush RheumNow ( View Tweet)
A common clinical phenotype arising from diverse pathogenic mechanisms. Study of PBMC transcriptomes (ACPA+ at-risk vs early ACPA+ RA vs controls). A TF signature was enriched in early RA & at-risk individuals (involving SUMOylation, RUNX2, YAP1, NOTCH3, β-Catenin). Cells w/… https://t.co/vCDEjIMXWa https://t.co/mizo7AXWvr
Dr. John Cush RheumNow ( View Tweet)
Australian population study of 14,041 RA pts (68% F; age 65 yrs) vs 33,785 controls, preexisting cancer (CA) in RA was less prevalent (7.6% vs 14.2%). Cancer incid. rates lower in RA (CIR 19.68 vs 24.77) & stable over 3 decades. RA CIR higher for lung (CIR 1.17) & heme CA (CIR… https://t.co/k5KRwYT6jl https://t.co/MVfmuTGlth
Dr. John Cush RheumNow ( View Tweet)
Three B-cell targeting anti-CD20 mAbs in clinical use:
- Rituximab (1997) for RA, GPA, CLL, NHL, Pemphigus Vulgaris
- Ofatumumab (2020) for relapsing MS
- Obinutuzumab (2013) for Follicular lymphoma & CLL
OFA & OBIN may be better than RTX in membranous GN pts w/ anti-RTX Abs… https://t.co/ZhUbXFXjSR https://t.co/vUHkS76PK7
Dr. John Cush RheumNow ( View Tweet)
Targeting PD-1 in Rheumatoid Arthritis
The results of the large Phase 2b RENOIR trial showed that rosnilimab, a monoclonal antibody targeting PD-1, was effective in moderate-to-severe rheumatoid arthritis (RA) patients.
https://t.co/ZsS3JOqdLh https://t.co/3JByNrLTGR
Links:
Dr. John Cush RheumNow ( View Tweet)
